RecruitingPhase 1NCT06655246

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kura Oncology, Inc.
Intervention: ziftomenib(drug)
Enrollment: 157 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2028

Study locations (30)

University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic Cancer Center, Phoenix, Arizona, United States
University of California, San Diego, La Jolla, California, United States
University of Southern California, Los Angeles, California, United States
University Of California, Irvine, Orange, California, United States
Stanford Cancer Institute, Palo Alto, California, United States
UCLA Santa Monica Medical Center, Santa Monica, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Sarah Cannon Research Institute, Denver, Colorado, United States
Yale University School of Medicine, New Haven, Connecticut, United States
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
University of Miami, Miami, Florida, United States
Northwestern University, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Johns Hopkins University, Baltimore, Maryland, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06655246 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor →

← Back to all trials